Microchip Biotechnologies Selected for Participation in the US Army Commercialization Pilot Program

Microchip Biotechnologies, Inc. (MBI) has been selected for participation in the inaugural US Army Commercialization Pilot Program. The Commercialization Pilot Program is a new program to identify SBIR firms that have Phase II projects with high transition potential to commercial products that meet high priority Army requirements.

MBI was identified as one of 25 firms selected out of 529 eligible firms and 416 applicants. MBI has been developing a biothreat detection system under Army SBIR funding.

"The acceptance of MBI by the Army to participate in the CPP is a further validation of our commitment to develop and commercialize microfluidic technologies for the protection of the combat troops and civilian populations," said Dr. Stevan Jovanovich, President and CEO of MBI.